Two‐decade battle with myasthenia gravis: A breakthrough case report on the long‐term success with eculizumab and ravulizumab treatment

Key Clinical Message This unique case of generalized myasthenia gravis shows sustained stability of a patient's condition for 3 years with eculizumab/ravulizumab treatment following 16 years of refractory disease. It highlights the long‐term effectiveness of C5 inhibitors in a real‐world settin...

Full description

Bibliographic Details
Published in:	Clinical Case Reports
Main Author:	Stefan Quasthoff
Format:	Article
Language:	English
Published:	Wiley 2024-11-01
Subjects:	eculizumab generalized myasthenia gravis myasthenia gravis ravulizumab
Online Access:	https://doi.org/10.1002/ccr3.9547

Similar Items

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
by: Antozzi C, et al.
Published: (2023-10-01)

Management of refractory generalized myasthenia gravis with eculizumab during pregnancy and puerperium: a case report
by: Bedriye Karaman, et al.
Published: (2025-10-01)

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
by: Tuan Vu, et al.
Published: (2021-02-01)

The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis
by: Armando Martinez Salazar, et al.
Published: (2025-05-01)

Role of complement in myasthenia gravis
by: Pyae Phyo San, et al.
Published: (2023-10-01)

Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
by: Florencia Aguirre, et al.
Published: (2024-10-01)

Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice
by: Nakul Katyal, et al.
Published: (2024-06-01)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
by: Waheed W, et al.
Published: (2022-08-01)

Real-World Case Series of Ravulizumab Use in Patients with Myasthenia Gravis in Romania
by: Crisanda Vîlciu, et al.
Published: (2025-03-01)

IMMUNOPATHOGENESIS OF MYASTHENIA GRAVIS (REVIEW)
by: E. D. Gasymly
Published: (2018-06-01)

Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab
by: Sara L. Weidmayer, et al.
Published: (2023-12-01)

Eculizumab Treatment of Massive Hemolysis Occurring in a Rare Co-Existence of Paroxysmal Nocturnal Hemoglobinuria and Myasthenia Gravis
by: Ráhel Réka Bicskó, et al.
Published: (2024-04-01)

Disease severity assessment and short-term outcome in patients with myasthenia gravis
by: Deepthi Vemuri, et al.
Published: (2020-01-01)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
by: Tuan Vu, et al.
Published: (2023-06-01)

Ocular myasthenia gravis management
by: Mark J. Kupersmith, et al.
Published: (2025-11-01)

Delayed diagnosis of distal myasthenia gravis: a case report
by: M. L. Cao, et al.
Published: (2024-11-01)

Seronegative Maternal Ocular Myasthenia Gravis and Delayed Transient Neonatal Myasthenia Gravis
by: Courtney Townsel, et al.
Published: (2016-03-01)

Pediatric ocular myasthenia gravis: Case report and literature review
by: Adriana Solano, et al.
Published: (2019-01-01)

Fetal Surveillance in Pregnancies with Myasthenia Gravis
by: Brîndușa Ana Cimpoca-Raptis, et al.
Published: (2021-11-01)

Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections
by: Yufei Deng, et al.
Published: (2025-07-01)

Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients
by: Pan Wang, et al.
Published: (2024-06-01)

Myasthenia Gravis in a Patient with HIV
by: Singh YN, et al.
Published: (2009-04-01)

Eculizumab as Additional Rescue Therapy in Myasthenic Crisis
by: Francesco Crescenzo, et al.
Published: (2024-02-01)

Clinical characteristics and outcomes of COVID-19 infection among myasthenia gravis patients in a national referral hospital in Indonesia
by: Fitri Octaviana, et al.
Published: (2023-09-01)

Myasthenia gravis in children: analysis of 18 patients
by: Morita Maria da Penha A., et al.
Published: (2001-01-01)

Clinical characteristics of late-onset myasthenia gravis
by: Chenjing Sun, et al.
Published: (2024-04-01)

Incidence and Prevalence of Juvenile Myasthenia Gravis in the United States Between 2010 and 2020: Analysis of Two Claims Databases
by: Jiachen Zhou, et al.
Published: (2025-05-01)

Congenital and Juvenile Myasthenia Gravis
by: J Gordon Millichap
Published: (1996-08-01)

Maintenance Therapy for Myasthenia Gravis
by: J Gordon Millichap, et al.
Published: (2014-07-01)

Ocular myasthenia gravis and thymoma
by: Victor Alegre-Ituarte, et al.
Published: (2022-09-01)

Национален консенсус за диагностика и лечение на myasthenia gravis
by: Ivan Milanov, et al.
Published: (2025-05-01)

Национален консенсус за диагностика и лечение на myasthenia gravis
by: Ivan Milanov, et al.
Published: (2023-04-01)

Национален консенсус за диагностика и лечение на myasthenia gravis
by: Ivan Milanov, et al.
Published: (2021-03-01)

Uncontrolled recurrent myasthenia gravis exacerbations secondary to chronic gabapentin use
by: Jason L. Chien, et al.
Published: (2019-07-01)

New‐Onset Myasthenia Gravis Mimics Spinal Cord Injury After Zenker's Diverticulum Repair
by: Steffen E. Meiler, et al.
Published: (2023-04-01)

Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities
by: Chi Ma, et al.
Published: (2024-05-01)

Novel Immunotherapies for Myasthenia Gravis
by: Nair SS, et al.
Published: (2023-04-01)

Ocular Myasthenia Gravis and Thymus Gland Hyperplasia–A Case Report
by: Sujit Das
Published: (2025-09-01)

Myasthenia gravis with Castleman disease: A case report with review of literature
by: Sujit Nandy, et al.
Published: (2025-04-01)

Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice
by: Lukas Theissen, et al.
Published: (2024-03-01)